FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. Maria A. Carballosa, M.D.

    FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.

    Medium
  2. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  3. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  4. Konrad Rejdak, M.D., Ph.D.

    FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.

    Medium
  5. Cipla Limited

    FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

    High risk
  6. Abbott Point of Care Canada Limited

    FDA says Abbott Point of Care Canada marketed modified i-STAT cTnI cartridges without required FDA clearance.

    High risk
  7. Valley Biosystems

    FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.

    High risk
  8. Vasyl Melnyk, M.D.

    FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.

    Medium
  9. KDunn and Associates, P.A. dba HealthQuilt

    Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.

    High risk